News

Public · Published

Amneal Pharmaceuticals, Inc reports results for the quarter ended September 30 - Earnings Summary

Amneal Pharmaceuticals reported quarterly adjusted earnings of 26 cents per share, above the 23-cent analyst average, while revenue rose 10% to $862.68 million, also beating estimates. However, reported earnings per share was a loss of 6 cents, and quarterly net income was $12.31 million.

Published:

Updated:

What happened

Amneal Pharmaceuticals reported quarterly adjusted earnings of 26 cents per share, above the 23-cent analyst average, while revenue rose 10% to $862.68 million, also beating estimates. However, reported earnings per share was a loss of 6 cents, and quarterly net income was $12.31 million.

Confirmed

Global impact / market context

Adjusted earnings strip out one-time items, so the gap between 26 cents adjusted profit and a 6-cent reported loss signals large special charges weighing on results. Investors must judge whether the underlying business strength is durable or flattered by adjustments, since reported profit ultimately drives book value.

Analyst inference

Shares gained 1.5% this quarter and 62.2% this year, with analysts unanimously rating the stock buy and a median target of $24.00, about 14.8% above the $20.44 close. Estimates rose 3.8% over three months with no negative revisions in 30 days, suggesting improving expectations.

Analyst inference

What to watch

  1. The exact nature and size of the charges separating 26 cents adjusted earnings from the 6-cent reported loss are not detailed, so the next filing should clarify what costs recur. Confirmed
  2. Watch whether analysts revise their $24.00 median price target after this beat, since no negative estimate revisions occurred in the past 30 days. Proposed
  3. Revenue growth of 10% outpacing analyst expectations suggests volume gains; watch whether this pace continues or reflects one-time product sales that could reverse next quarter. Analyst inference

Evidence

  • Original source link unavailable